Table 1.
Author’s summary of the evidence for combination therapy
|
Crohn’s disease |
Ulcerative colitis |
|||
| Clinical benefit | Pharmacokinetic/immunogenic benefit | Clinical benefit | Pharmacokinetic/immunogenic benefit | |
| IFX + AZA/6MP (treatment naïve) | + | + | + | + |
| IFX + AZA/6MP (step-up from immunomodulator monotherapy) | - | NA | NA | NA |
| IFX + MTX | +/- | + | NA | NA |
| ADA + IMM | +/- | +/- | NA | NA |
| VDZ + IMM | NA | + | NA | NA |
| Ustekinumab + | NA | NA | NA | NA |
| IMM | ||||
IFX: Infliximab; AZA: Azathioprine; 6-MP: 6-mercaptopurine; MTX: Methotrexate; ADA: Adalimumab; VDZ: Vedolizumab; IMM: immunomodulatory; +: beneficial; +/-: Possible benefit; NA: No adequate data available.